London — Two of the world’s biggest vaccine makers are joining forces to tackle the coronavirus as the number of confirmed infections approaches 2-million worldwide.

Sanofi will test its experimental coronavirus vaccine with GlaxoSmithKline (GSK) supplying adjuvants, which are additional ingredients that improve efficacy and make it easier to produce shots in larger quantities, the companies said on Tuesday. The drugmakers said they plan to start human trials in the second half of this year, with the goal of having a vaccine available by the second half of 2021 if the studies are successful...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now